[Pharmacologic profile of urapidil. Consequences for use as an antihypertensive drug].
Urapidil, a phenylpiperazine-substituted derivative of uracil, is an example of an anti-hypertensive which lowers elevated blood pressure via at least two different mechanisms. As such, it belongs to the multifactorial or hybrid anti-hypertensives. Urapidil is a peripherally acting alpha 1-adrenoceptor antagonist, and, in this regard, is comparable with prazosin and its successor compounds (e.g. doxazosin). In addition, urapidil lowers elevated blood pressure via a central mechanism which is new and differs from that of the classical antihypertensives with a central nervous effect (clonidine, etc.). This additional mechanism favourably influences the side effect profile of urapidil.
Abteilungen Pharmakotherapie und Kardiologie, Medizinische Fakultät, Akademisch Medizinisches Zentrum, Amsterdam.
P A
PA
van Zwieten
D000317:Adrenergic alpha-Antagonists / Q000493:pharmacokinetics / Q000627:therapeutic use*; D000959:Antihypertensive Agents / Q000493:pharmacokinetics / Q000627:therapeutic use*; D006439:Hemodynamics / Q000187:drug effects*; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D010879:Piperazines / Q000493:pharmacokinetics / Q000627:therapeutic use*; D011942:Receptors, Adrenergic, alpha / Q000187:drug effects*
D000317:Adrenergic alpha-Antagonists; D000959:Antihypertensive Agents; D010879:Piperazines; D011942:Receptors, Adrenergic, alpha; C015568:urapidil
Pharmakologisches Profil von Urapidil. Konsequenzen für die Anwendung als Antihypertensivum.